From October 17–21, BIOEMTECH participated in the EANM 2026 Annual Congress in Vienna, one of the leading international gatherings for the nuclear medicine community.
Throughout the congress, we had the pleasure of welcoming researchers, collaborators and industry professionals to our booth, exchanging ideas, discussing ongoing projects and exploring new opportunities for collaboration in radiopharmaceutical research.
This year’s participation was particularly exciting for us, as we showcased our latest developments in preclinical molecular imaging, with a special focus on the expanded capabilities of our γ-eye™ SPECT system. Visitors had the opportunity to explore new imaging data with ²²⁵Ac and ¹⁷⁷Lu, including advanced 3D SPECT applications, and learn more about our dynamic and longitudinal imaging capabilities.
We also had the opportunity to discuss how our eyes™ imaging systems and integrated preclinical CRO services can support radiopharmaceutical development, from early-stage research to translational studies.
We would like to sincerely thank everyone who visited our booth, shared their insights and took the time to connect with our team.
Events like EANM remind us of the importance of scientific exchange and collaboration in advancing molecular imaging and radiopharmaceutical research.
We look forward to continuing these conversations and seeing everyone again at future events!